Dana Farber Cancer Insitute - Ligon Lab Research

Dr Keith Ligon's research work at Dana Farber - Ligon Lab covers PERSONALIZED MEDICINE AND BRAIN TUMOR RESEARCH.
"Biology of patient derived cancer models and preclinical investigation.
A major limitation to development of more effective cancer therapies is the paucity of human cancer models which accurately represent the diversity of cancer phenotypes and genotypes seen in patients. To begin to address this our lab created an enterprise-wide Living Tissue Bank and we have created more than 1000 patient models including primary cell cultures, patient derived cell lines (PDCL), and patient derived xenografts (PDX) from more than 15 different cancer types in collaboration with the Beroukhim Lab. We used 70 GBM cell lines in a 400-drug screen to identify MDM2 inhibitors as one of the most effective agents in GBM PDCL and PDX models. In breast to brain PDX models we, with the Zhao Lab, identified combined PI3K and MTOR inhibition as a highly effective therapy capable of inducing durable remissions in HER2+ PDX models.Both studies led to clinical trials in patients and we are currently working with Dr. Patrick Wen and others to analyze these studies.The Center for Patient Derived Models, which Dr. Ligon directs, is a key collaborator in institutional model creation efforts, as well as creating and distributing models for other investigators for all cancer types. See the CPDM page to learn more".

https://ligonlab.dana-farber.org/research.html

Trial Research from Dr Patrick Wen and Dr Priscilla Brastianos cannot be under estimated.

Regards.